At this time, SOTIO does not offer expanded access or compassionate use programs for neither SOT106 nor SOT109. Access to SOT106 and to SOT109 are currently limited to participation in authorized clinical trials. Information regarding the current clinical trials can be found in ClinicalTrials.gov (NCT07801222 and NCT07693751).
As SOT106 and SOT109 are in the early stages of clinical development, the establishment of expanded access programs will be evaluated as development progresses. Should an expanded access program become available in the future, requests will be evaluated on a case-by-case basis based on clinical criteria, drug availability, and in accordance with applicable regulations and company policy. For general inquiries, please contact: clinicaltrial@sotio.com. Inquiries will be acknowledged within approximately 5–10 business days.